QTORIN Rapamycin Gel for Microcystic Lymphatic Malformations

QTORIN Rapamycin Gel for Microcystic Lymphatic Malformations
75%64%53%Feb 17Feb 18Feb 19Feb 20Feb 21Feb 22Feb 23Feb 24Feb 25Feb 26Feb 27Feb 28Mar 1Mar 2Mar 3Mar 4Mar 5Mar 6Mar 7Mar 8Mar 9Mar 10Mar 11Mar 12Mar 13Mar 14Mar 15Mar 16Mar 17Mar 18Mar 19Mar 20Mar 21Mar 22Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29Mar 30Mar 31Apr 1Apr 2Apr 3Apr 4Apr 5Apr 6Apr 7Apr 8Apr 9Apr 10Apr 11Apr 12Apr 13Apr 14Apr 15Apr 16Apr 17Apr 18Apr 19Apr 20Apr 21Apr 22Apr 23Apr 24Apr 25Apr 26Apr 27Apr 28Apr 29Apr 30May 1May 2May 3May 4May 5May 6May 7May 8May 9May 10May 11May 12May 13May 14May 15May 16May 17May 18May 19May 20May 21May 22May 23May 24May 25May 21 • YES 62.0%May 22 • YES 62.8%May 23 • YES 63.5%May 24 • YES 64.7%May 25 • YES 65.1%
Palvella Therapeutics, Inc. ($PVLA)
No stock closeNo stock close$126.9$100.0$73.07Feb 17Feb 18Feb 19Feb 20Feb 21Feb 22Feb 23Feb 24Feb 25Feb 26Feb 27Feb 28Mar 1Mar 2Mar 3Mar 4Mar 5Mar 6Mar 7Mar 8Mar 9Mar 10Mar 11Mar 12Mar 13Mar 14Mar 15Mar 16Mar 17Mar 18Mar 19Mar 20Mar 21Mar 22Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29Mar 30Mar 31Apr 1Apr 2Apr 3Apr 4Apr 5Apr 6Apr 7Apr 8Apr 9Apr 10Apr 11Apr 12Apr 13Apr 14Apr 15Apr 16Apr 17Apr 18Apr 19Apr 20Apr 21Apr 22Apr 23Apr 24Apr 25Apr 26Apr 27Apr 28Apr 29Apr 30May 1May 2May 3May 4May 5May 6May 7May 8May 9May 10May 11May 12May 13May 14May 15May 16May 17May 18May 19May 20May 21May 22May 23May 24May 25Feb 17 • PVLA $80.09Feb 18 • PVLA $79.60Feb 19 • PVLA $82.33Feb 20 • PVLA $85.66Feb 23 • PVLA $87.84Feb 24 • PVLA $120.4
ResolvedPositive
Oracle Evidence
ClinicalNewsTrialPositionsReasoningOracle

Matched news5 items

All news
PVLA

Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular Malformations

In SELVA Phase 3 study, 100% of participants (13/13) aged 6–11 years were rated as “Much Improved” (+2) or “Very Much Improved” (+3) on the Microcystic Lymphatic Malformation Investigator Global Assessment (mLM-IGA) scale at Week 24, with a mean improvement of +2.46 (p

Presentation / Abstract • Phase 3ISSVA World Congress presentation Wed, May 20, 2026Matched qtorin, rapamycin, microcystic, lymphatic, malformations
PVLA

Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology

100% of patients with bleeding at baseline demonstrated a statistically significant improvement on the Cutaneous Venous Malformations Investigator Global Assessment Bleeding scale (cVM-IGA Bleeding) at Week 12 (+2.5 point improvement; p=0.003) 100% of patients with bleeding at baseline reported

Presentation / Abstract • Phase 2Matched qtorin, rapamycin, microcystic, lymphatic, malformations
PVLA

Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026

James Treat, MD, Professor of Clinical Pediatrics and Dermatology at the Children’s Hospital of Philadelphia to present clinical results on Wednesday, May 20, 2026, at 4:30 p.m. ET WAYNE, Pa., April 20, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc.

Presentation / Abstract • Phase 3Matched qtorin, rapamycin, microcystic, lymphatic, malformations
PVLA

Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas

Clinically significant angiokeratomas represent a rare, chronic and debilitating lymphatic malformation with no FDA-approved therapies and an estimated more than 50,000 diagnosed patients in the U.S. Phase 2 single-arm, baseline-controlled trial expected to enroll up to 15 subjects at leading

Trial Start • Phase 2Matched qtorin, rapamycin, microcystic, lymphatic, malformations